CM – Allergy Therapeutics stocks rise on positive G309 study results

0

Morningstar.co.uk contains data, news and research on stocks and funds, unique commentary and independent Morningstar research on a wide range of investment products, as well as portfolio and asset allocation tools to help you make better investment decisions. </ (Alliance News) – Allergy Therapeutics PLC reported positive results Monday from the G309 exploratory field study evaluating the efficacy and safety of Grass MATA MPL.

Grass MATA MPL is a short-term subcutaneous allergen-specific immunotherapy candidate aimed at the Combating the cause of the symptoms of allergic rhinoconjunctivitis by using grass pollen.

Two short cycles of six injections with a treatment duration of six and 14 weeks were tested.

AIM-listed Allergy Therapeutics shares traded 14% higher in London on Monday at 38.17 pence each.

The Worthing, England-based pharmaceutical company said the G309 study was a double-blind, placebo-controlled, randomized study over one year that enrolled 119 patients in 14 locations in Germany and the United States.

Allergy Therapeutics highlighted that the primary endpoint of the composite symptom medication score was met with clinically relevant improvement in both active treatment groups compared to placebo.

These study results will be used to design the upcoming pivotal phase III study The company announced that it will start optimizing in the second half of 2022 in the EU and the US.

« We are pleased to announce these results, which show a clear treatment effect against our novel short-term immunotherapy Show grass pollen allergies, « said CEO Manuel Llobet.

« The results will enable us to optimize the upcoming pivotal Phase III G306 field study, maximize the chance of success and support our regulatory plans for entry into the US, » added Llobet.

Kore Potash PLC – Kola and DX Potash Projects in Republic of the Congo – Announces Process …

(Alliance News) – Kefi Gold & Copper PLC said Monday that four workers were kidnapped while …

Mining companies operate in a challenging environment, but now may be the time to …

In this series, we ask leading fund managers everything from their investment strategy to their …

The Morningstar Star Rating for stocks is based on an analyst estimate of the fair value of the stock. It is a projection / opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of the fair value of a stock. Four components determine the star rating: (1) our assessment of the company’s economic divide, (2) our estimate of the fair value of the share, (3) our uncertainty regarding this estimate of the fair value and (4) the current market price. This process culminates in a one-point star rating that is updated daily. A 5-star rating represents the belief that the stock has good value at its current price; it is not a 1-star share. If our assumptions are correct in the base case, the market price will approach our fair value estimate over time, usually within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be maintained in the future and is not an indication of future performance. Detailed information on the Morningstar Star Rating for Stocks can be found here

The Quantitative Fair Value Estimate is Morningstar’s estimate of the dollar amount per share that a company’s equity is worth today. The quantitative fair value estimate is based on a statistical model derived from the fair value estimate that Morningstar’s equity analysts attribute to the companies and which contains a financial forecast for the company. The quantitative fair value estimate is calculated daily. It is a projection / opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be maintained in the future and is not an indication of future performance. You can find detailed information on the quantitative fair value estimate here

Keywords:

Allergy Therapeutics,Allergic rhinitis,Pollen,LON:AGY,Allergy Therapeutics, Allergic rhinitis, Pollen, LON:AGY,,,,,,,,ALLWEB,ALLPRO,ALLALL,ALLSIG,ALLPOS,ALLENL,ALL.AGY,ALL.AGY=ABOUT,ALLAIM,ALL4000,ALL4570,GB00B02LCQ05,ALLTST,ALLCOS,ALLPDT,ALLCOS,

Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: